UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549  

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934 

 

Date of report (Date of earliest event reported): January 13, 2020

 

ACRO BIOMEDICAL CO., LTD.

(Exact name of registrant as specified in Charter)

  

Nevada

 

333-207765

 

47-1950356

(State or other jurisdiction of

incorporation or organization)

 

(Commission File No.)

 

(IRS Employee Identification No.)

 

12175 Visionary Way, Suite 1160; Fishers, Indiana 46038

 (Address of Principal Executive Offices)

 

(317) 286-6788

 (Registrant’s Telephone number)

Copies to:

Asher S. Levitsky PC

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas, Suite 1100

New York, New York 10105

Phone: (646) 895-7152

Fax: (212) 370-7889

E-mail: alevitsky@egsllp.com

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 
 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

On January 13, 2020, the sole director of the Company determined to change the fiscal year of the Company from the year ending September 30 to the calendar year, effective with the year ended December 31, 2019. The change of fiscal year will be reflected in a Form 10-K for the year ended December 31, 2019.

 

 

2

 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 17, 2020

ACRO BIOMEDICAL CO., LTD.

 

 

 

 

 

 

 

By:  

/s/ Pao-Chi Chu

 

 

 

Pao-Chi Chu

 

 

 

Chief Executive Officer

 

 

 

3

 

Arco Biomedical (CE) (USOTC:ACBM)
過去 株価チャート
から 11 2024 まで 12 2024 Arco Biomedical (CE)のチャートをもっと見るにはこちらをクリック
Arco Biomedical (CE) (USOTC:ACBM)
過去 株価チャート
から 12 2023 まで 12 2024 Arco Biomedical (CE)のチャートをもっと見るにはこちらをクリック